Therapy of uncomplicated falciparum malaria: a randomized trial comparing artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in Irian Jaya, Indonesia.

E Tjitra National Institute of Health Research and Development, Ministry of Health, Jakarta, Indonesia.

Search for other papers by E Tjitra in
Current site
Google Scholar
PubMed Close
,
S Suprianto National Institute of Health Research and Development, Ministry of Health, Jakarta, Indonesia.

Search for other papers by S Suprianto in
Current site
Google Scholar
PubMed Close
,
B J Currie National Institute of Health Research and Development, Ministry of Health, Jakarta, Indonesia.

Search for other papers by B J Currie in
Current site
Google Scholar
PubMed Close
,
P S Morris National Institute of Health Research and Development, Ministry of Health, Jakarta, Indonesia.

Search for other papers by P S Morris in
Current site
Google Scholar
PubMed Close
,
J R Saunders National Institute of Health Research and Development, Ministry of Health, Jakarta, Indonesia.

Search for other papers by J R Saunders in
Current site
Google Scholar
PubMed Close
, and
N M Anstey National Institute of Health Research and Development, Ministry of Health, Jakarta, Indonesia.

Search for other papers by N M Anstey in
Current site
Google Scholar
PubMed Close
DOI:
https://doi.org/10.4269/ajtmh.2001.65.309
Volume/Issue:
Volume 65: Issue 4
Page(s):
309–317
Restricted access
Get Permissions

Combining artesunate with existing antimalarial drugs may improve cure rates, delay emergence of resistance, and reduce transmission. We performed a randomized comparative trial to quantify the effect of adding artesunate to sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria in Indonesia. Using a modified 1997 World Health Organization protocol for assessment of therapeutic efficacy of antimalarial drugs, 105 patients (stratified by age/ethnic group) were randomized: 53 received artesunate orally, 4 mg/kg of body weight, a single daily dose for three days, plus sulfadoxine-pyrimethamine orally (1.25 mg of pyrimethamine/kg of body weight), a single dose on day 0, and 52 patients received sulfadoxine-pyrimethamine alone. Six from the combination group were withdrawn from analysis, as were six of the sulfadoxine-pyrimethamine group. Treatment failure rates on day 14 were 0% in the artesunate plus sulfadoxine-pyrimethamine group and 8.7% in the sulfadoxine-pyrimethamine group (P = 0.12). Treatment failure rates on day 28 were 4.4% and 15.2%, respectively (P = 0.16). Relative risk of treatment failure at 28 days was 0.3 (95% confidence interval [CI] = 0.1-1.3). Mean fever clearance time (1.3 versus 1.7 days) and mean parasite clearance time (1.4 versus 2.0 days) were both faster in the artesunate plus sulfadoxine-pyrimethamine group than in the sulfadoxine-pyrimethamine group (P = 0.08 and P < 0.0001, respectively). Only 20 (39.2%) of 51 patients treated with artesunate plus sulfadoxine-pyrimethamine were still parasitemic on day 1 compared with 45 (86.5%) of 52 patients treated with sulfadoxine-pyrimethamine alone (P = 0.000001, relative risk [RR] = 0.4, 95% CI = 0.3-0.6). Gametocyte carriage was lower following artesunate plus sulfadoxine-pyrimethamine than following sulfadoxine-pyrimethamine (RR = 0.5, 95% CI = 0.2-1.0 on day 7 and RR = 0.5, 95% CI = 0.2-1.1 on day 14). Mild diarrhea, rash, and itching resolved without treatment. Combined artesunate plus sulfadoxine-pyrimethamine resulted in more rapid fever and parasiteclearance, was well tolerated, reduced risk of treatment failure, and lowered gametocyte carriage.

Author Notes

Published Online:
Oct 2001
Cover The American Journal of Tropical Medicine and Hygiene
The American Journal of Tropical Medicine and Hygiene
Print ISSN:
0002-9637
Past two years Past Year Past 30 Days
Abstract Views 221 191 46
Full Text Views 145 4 1
PDF Downloads 44 4 1
 
 
 
 
Affiliate Membership Banner
 
 
Research for Health Information Banner
 
 
CLOCKSS
 
 
 
Society Publishers Coalition Banner
Save